Remove 2009 Remove Biosimilars Remove Immunity
article thumbnail

ADA: Vertex closer to weaning type 1 diabetics off insulin

pharmaphorum

Vertex was also developing a version of the therapy called VX-264 in which the cells were encapsulated in a protective device designed to protect them from rejection by the immune system, but that failed to hit the mark in early clinical testing and has been dropped. Oncology Merck and oncology: A conversation with Dr Gregory Lubinieck.

article thumbnail

Nitisinone Becomes First and Only FDA-Approved Treatment for HGA in Adults With AKU

Pharmacy Times

With this action, nitisinone is the first and only FDA-approved treatment for AKU. 1 AKU, also known as black urine disease, is a rare inherited disorder that prevents the patient’s body from completely breaking down 2 amino acids, tyrosine and phenylalanine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics

PharmaTech

Some companies are combining mRNA vaccines with programmed cell death protein 1 (PD-1) inhibitors to activate the immune system and elicit tumour-specific T-cell responses. The LNPs provide targeted delivery of the mRNA directly to tumours, resulting in strong immune activation, tumour elimination, and durable immunological responses.

article thumbnail

Nektar eyes pivotal trials for eczema drug cast off by Lilly

pharmaphorum

Breaking into that could be a challenge for Nektar, but the company said in a statement that the rapid improvement in EASI scores and reduction of itch in REZOLVE-AD "show potential differentiation of this novel regulatory T-cell mechanism as a first and best-in-class immune-modulator." pharmaphorum – an EVERSANA company

article thumbnail

AbbVie's $2.1bn buy of Capstan lifts its immunology pipeline

pharmaphorum

It is delivered directly to patients using a proprietary lipid nanoparticle formulation (LNP) that can be aimed at specific cells using a targeting component, such as an antibody, carrying an mRNA that encodes an anti-CD19 CAR that can reprogramme CD8-expressing cytotoxic T-cells and "reset" the immune system.

article thumbnail

ACIP backs block on flu vaccines with thimerosal additive

pharmaphorum

The CDCs newly constituted Advisory Committee on Immunization Practices (ACIP) has voted to recommend the removal of vaccine preservative, thimerosal, that has become a focal point for activists trying to link vaccines to autism. Website and content copyright © 2009- 2025 , pharmaphorum media limited or its licensors; all rights reserved.

article thumbnail

Optimising bispecific antibody clonal cell selection with high-throughput analytics

European Pharmaceutical Review

2 A bsAb can have clinical advantages over conventional monoclonal antibodies (mAbs) including targeting functionally interrelated checkpoint inhibitors, directing immune responders to cancer cells, enhancing specificity and decreasing off-target toxicity. 2017 Aug 1;28(8):2009-2012. Available at: doi.org/10.1016/j.ctrv.2021.102240.